[18F]-FDG Uptake as a Marker of Residual Anaplastic and Poorly Differentiated Thyroid Carcinoma following BRAF-Targeted Therapy [CLINICAL]

BACKGROUND AND PURPOSE:
Neoadjuvant BRAF-directed therapy and immunotherapy followed by surgery improves survival in patients with BRAFV600E-mutant anaplastic thyroid carcinoma (ATC), more so in those who have complete ATC pathologic response. This study assesses the ability of FDG-PET to noninvasively detect residual high-risk pathologies including ATC and poorly differentiated thyroid carcinoma (PDTC) in the preoperative setting.

MATERIALS AND METHODS:
This retrospective, single-center study …

Read the full article on ajnr.org